Cyclooxygenase-2 is involved in oxidative damage and alpha-synuclein accumulation in dopaminergic cells

Neuroscience Letters

Volumn 436, Issue 2, 2008, Pages 205-209

  Chae, Sung Wook ^a   Kang, Bok Yun ^a   Hwang, Onyou ^b   Choi, Hyun Jin ^a  

^a Chonnam National University   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

Author keywords

Synuclein; Cyclooxygenase 2 (COX 2); Dopamine; Oxidative stress; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; CYCLOOXYGENASE 2; DOPAMINE; MELOXICAM;

ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; OXIDATION; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MODIFICATION;

ALPHA-SYNUCLEIN; CELL LINE, TUMOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; GENE EXPRESSION; HEMIN; HUMANS; NEUROBLASTOMA; OXIDATIVE STRESS; SPECTROMETRY, FLUORESCENCE; THIAZINES; THIAZOLES; TIME FACTORS; TRANSFECTION;

EID: 41949108084     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2008.03.031     Document Type: Article

References (30)

1. Alam Z.I., Daniel S.E., Lees A.J., Marsden D.C., Jenner P., and Halliwell B. A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J. Neurochem. 69 (1997) 1326-1329
2. Asanuma M., Miyazaki I., and Ogawa N. Dopamine- or l-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease. Neurotox. Res. 5 (2003) 165-176
3. Barzilai A., Melamed E., and Shirvan A. Is there a rationale for neuroprotection against dopamine toxicity in Parkinson's disease?. Cell. Mol. Neurobiol. 21 (2001) 215-235
4. Chae S.-W., Bang Y.J., Kim K.-M., Lee K.Y., Kang B.Y., Kim E.M., Inoue H., Hwang O., and Choi H.J. Role of cyclooxygenase-2 in tetrahydrobiopterin-induced dopamine oxidation. Biochem. Biophys. Res. Commun. 359 (2007) 735-741
5. Conway K.A., Rochet J.C., Bieganski R.M., and Lansbury Jr. P.T. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 294 (2001) 1346-1349
6. Dawson T.M., and Dawson V.L. Molecular pathways of neurodegeneration in Parkinson's disease. Science 302 (2003) 819-822
7. Dunnett S.B., and Bjorklund A. Prospects for new restorative and neuroprotective treatments in Parkinson's disease. Nature 399 (1999) A32-A39
8. Emdadul Haque M., Asanuma M., Higashi Y., Miyazaki I., Tanaka K., and Ogawa N. Apoptosis-inducing neurotoxicity of dopamine and its metabolites via reactive quinone generation in neuroblastoma cells. Biochim. Biophys. Acta 1619 (2003) 39-52
9. Eriksen J.L., Dawson T.M., Dickson D.W., and Petrucelli L. Caught in the act: alpha-synuclein is the culprit in Parkinson's disease. Neuron 40 (2003) 453-456
10. Everse J., and Coates P.W. Role of peroxidases in Parkinson disease: a hypothesis. Free Radic. Biol. Med. 38 (2005) 1296-1310
11. Floor E., and Wetzel M.G. Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay. J. Neurochem. 70 (1998) 268-275
12. Galzigna L., Schiappelli M.P., Rigo A., and Scarpa M. A rat brain fraction and different purified peroxidases catalyzing the formation of dopaminochrome from dopamine. Biochim. Biophys. Acta 1427 (1999) 329-336
13. Gille G., Hung S.T., Reichmann H., and Rausch W.D. Oxidative stress to dopaminergic neurons as models of Parkinson's disease. Ann. N.Y. Acad. Sci. 1018 (2004) 533-540
14. Graham S.H., and Hickey R.W. Cyclooxygenases in central nervous system diseases: a special role for cyclooxygenase 2 in neuronal cell death. Arch. Neurol. 60 (2003) 630-632
15. Hastings T.G. Enzymatic oxidation of dopamine: the role of prostaglandin H synthase. J. Neurochem. 64 (1995) 919-924
16. Hastings T.G., Lewis D.A., and Zigmond M.J. Reactive dopamine metabolites and neurotoxicity: implications for Parkinson's disease. Adv. Exp. Med. Biol. 387 (1996) 97-106
17. Hastings T.G., and Zigmond M.J. Loss of dopaminergic neurons in parkinsonism: possible role of reactive dopamine metabolites. J. Neural Transm. Suppl. 49 (1997) 103-110
18. Hirsch E.C., Breidert T., Rousselet E., Hunot S., Hartmann A., and Michel P.P. The role of glial reaction and inflammation in Parkinson's disease. Ann. N.Y. Acad. Sci. 991 (2003) 214-228
19. Hirsch E., Graybiel A.M., and Agid Y.A. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 334 (1988) 345-348
20. Lang A.E., and Lozano A.M. Parkinson's disease. Second of two parts. N. Engl. J. Med. 339 (1998) 1130-1143
21. Li H.T., Lin D.H., Luo X.Y., Zhang F., Ji L.N., Du H.N., Song G.Q., Hu J., Zhou J.W., and Hu H.Y. Inhibition of alpha-synuclein fibrillization by dopamine analogs via reaction with the amino groups of alpha-synuclein. Implication for dopaminergic neurodegeneration. FEBS J. 272 (2005) 3661-3672
22. Lotharius J., and Brundin P. Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. Nat. Rev. Neurosci. 3 (2002) 932-942
23. Maker H.S., Weiss C., Silides D.J., and Cohen G. Coupling of dopamine oxidation (monoamine oxidase activity) to glutathione oxidation via the generation of hydrogen peroxide in rat brain homogenates. J. Neurochem. 36 (1981) 589-593
24. Okun M.R. The role of peroxidase in neuromelanin synthesis: a review. Physiol. Chem. Phys. Med. NMR 29 (1997) 15-22
25. Olanow C.W. The scientific basis for the current treatment of Parkinson's disease. Annu. Rev. Med. 55 (2004) 41-60
26. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., and Goedert M. Alpha-synuclein in Lewy bodies. Nature 388 (1997) 839-840
27. Teismann P., Tieu K., Choi D.K., Wu D.C., Naini A., Hunot S., Vila M., Jackson-Lewis V., and Przedborski S. Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 5473-5478
28. Tyurina Y.Y., Kapralov A.A., Jiang J., Borisenko C.G., Potapovich A.I., Sorokin A., Kochanek P.M., Graham S.H., Schor N.F., and Kagan V.E. Oxidation and cytotoxicity of 6-OHDA are mediated by reactive intermediates of COX-2 overexpressed in PC12 cells. Brain Res. 1093 (2006) 71-82
29. Vila M., and Przedborski S. Genetic clues to the pathogenesis of Parkinson's disease. Nat. Med. Suppl. (2004) S58-S62
30. Weingarten P., and Zhou Q.Y. Protection of intracellular dopamine cytotoxicity by dopamine disposition and metabolism factors. J. Neurochem. 77 (2001) 776-785